Pfizer CEO Anticipates EUA for COVID-19 Vaccine in Late November

Pfizer will not seek Emergency Use Authorization (EUA) for its COVID-19 vaccine until the end of November even if the readout from a Phase III study expected later this month is positive.

This morning, Pfizer Chief Executive Officer Albert Bourla posted an open letter on the company’s website explaining three key metrics the experimental vaccine for the novel coronavirus must meet before the company and its partner, Germany’s BioNTech will seek EUA.